Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESTO Trial
2024-512980-29-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, docetaxel, oxaliplatin, fluorouracil and folinic acid in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Clinical and pathological complete response rate at endoscopic re-evaluation. Planned start Aug 2023; status: authorised.
02
Drugs
durvalumabdocetaxeloxaliplatinfluorouracilfolinic acid
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-512980-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512980-29-00.